External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics and portfolio deepening in the India, South Africa, North America and key regulated and emerging markets.</li><li>Cipla’s strengths in respiratory, antiretrovirals, urology, cardiology, anti-infectives and CNS segments are well known.</li><li>The company has 47 manufacturing facilities around the world, producing more than 50 dosage forms and more than 1,500 products using state-of-the-art technology platforms to serve more than 80 markets.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics and portfolio deepening in the India, South Africa, North America and key regulated and emerging markets.Cipla’s strengths in respiratory, antiretrovirals, urology, cardiology, anti-infectives and CNS segments are well known.The company has 47 manufacturing facilities around the world, producing more than 50 dosage forms and more than 1,500 products using state-of-the-art technology platforms to serve more than 80 markets.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week - CIPLA LTD - 14 AUG 2023

Cipla Ltd

Pick of the Week - CIPLA LTD - 14 AUG 2023